Mast cells: A new target in the treatment of complex regional pain syndrome?

Pain Practice

Volumn 13, Issue 8, 2013, Pages 599-603

  Dirckx, Maaike ^a   Groeneweg, George ^a   van Daele, Paul L A ^a   Stronks, Dirk L ^a   Huygen, Frank J P M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Complex regional pain syndromes; Cytokines; Mast cells; Pathophysiology; Treatment

Indexed keywords

AZELASTINE; CETIRIZINE; CROMOGLYCATE DISODIUM; GLUCOCORTICOID; HISTAMINE; IMATINIB; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; LORATADINE; MONOKINE; RANITIDINE; SUNITINIB; THALIDOMIDE; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR;

ANALGESIA; ARTICLE; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CELL ACTIVITY; CELL DIFFERENTIATION; CELL DIVISION; CELL KILLING; CELL MEMBRANE FLUIDITY; CELL STIMULATION; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM SENSITIZATION; CHEMOTAXIS; CHRONIC MYELOID LEUKEMIA; COMPLEX REGIONAL PAIN SYNDROME; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG INHIBITION; HISTAMINE RELEASE; HUMAN; KIDNEY CARCINOMA; LIPID BILAYER; MAST CELL; MAST CELL DEGRANULATION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; TARGET CELL;

COMPLEX REGIONAL PAIN SYNDROMES; CYTOKINES; MAST CELLS; PATHOPHYSIOLOGY; TREATMENT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CENTRAL NERVOUS SYSTEM SENSITIZATION; COMPLEX REGIONAL PAIN SYNDROMES; HUMANS; INFLAMMATION; MAST CELLS;

EID: 84887404819     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/papr.12049     Document Type: Article

References (36)

1. Harden RN, Bruehl SP. Diagnosis of complex regional pain syndrome. Signs, symptoms, and new empirically derived diagnostic criteria. Clin J Pain. 2006;22:415-419.
2. de Mos M, de Brijn AGJ, Huygen FJPM, Dieleman JP, Stricker B, Sturkenboom MCJM. The incidence of complex regional pain syndrome: a population based study. Pain. 2007;129:12-20.
3. de Mos M, Huygen FJPM, van der Hoeven-Borgman M, Dieleman JP, Stricker B, Sturkenboom MCJM. Disease outcome of complex regional pain syndrome. Clin J Pain. 2009;25:590-597.
4. de Mos M, Sturkenboom MC, Huygen FJ. Current understandings on complex regional pain syndrome. Pain Pract. 2009;9:86-99.
5. Dirckx M, Stronks DL, Groeneweg G, Huygen FJPM. Effect of immunomodulating medications in complex regional pain syndrome. A systematic review. Clin J Pain. 2012;28:355-363.
6. Huygen FJMP, Ramdhani N, van Toorenbergen A, Klein J, Zijlstra FJ. Mast cells are involved in inflammatory reactions during complex regional pain syndrome type I. Immunol Lett. 2004;91:147-154.
7. Veldman PH, Reynen HM, Arntz IE, Goris RJ. Signs and symptoms of reflex sympathetic dystrophy: prospective study of 829 patients. Lancet. 1993;342:1012-1016.
8. Bruehl S. An update on the pathophysiology of complex regional pain syndrome. Anesthesiology. 2010;113:713-725.
9. Uçeyler N, Erberle T, Rolke R, Birklein F, Sommer C. Differential expression patterns of cytokines in complex regional pain syndrome. Pain. 2007;132:195-205.
10. Schinkel C, Scherens A, Köller M, Roellecke G, Muhr G, Maier C. Systemic inflammatory mediators in post-traumatic complex regional pain syndrome (CRPS I) - longitudinal investigations and differences to control groups. Eur J Med Res. 2009;14:130-135.
11. Oyen WJ, Arntz IE, Claessens RM, Van der Meer JW, Corstens FH, Goris RJ. Reflex sympathetic dystrophy of the hand: an excessive inflammatory response? Pain. 1993;55:2179-2184.
12. Bernateck M, Karst M, Gratz KF, et al. The first scintigraphic detection of tumor necrosis factor-alpha in patients with complex regional pain syndrome. Anesth Analg. 2010;110:211-215.
13. Huygen FJPM, de Bruijn AGJ, de Bruin MT, Groeneweg JG, Klein J, Zijlstra FJ. Evidence for local inflammation in complex regional pain syndrome type 1. Mediators Inflamm. 2002;11:47-51.
14. Wesseldijk F, Huygen FJPM, Heijmans-Antonissen C, Niehof SP, Zijlstra FJ. Tumor necrosis factor-α and interleukin-6 are not correlated with the characteristics of CRPS type 1 in 66 patients. Eur J Pain. 2008;12:716-721.
15. Wesseldijk F, Huygen FJPM, Heijmans-Antonissen C, Niehof SP, Zijlstra FJ. Six years of follow-up of the levels of TNF-α and IL-6 in patients with CRPS type 1. Mediators Inflamm. 2008;2008:469439.
16. Heijmans-Antonissen C, Wesseldijk F, Munnikes RJ, et al. Multiplex bead array assay for detection of 25 soluble cytokines in blister fluid of patients with complex regional pain syndrome type I. Mediators Inflamm. 2006;2006:283398.
17. Purcell WM, Atterwill CK. Mast cells in neuroimmune function: neurotoxicological and neuropharmacological perpectives. Neurochem Res. 1995;20:521-532.
18. Black PH. Stress and the inflammatory response: a review of neurogenic inflammation. Brain Behav Immun. 2002;16:622-653.
19. Bacci S, Romagnoli P. Drugs acting on mast cells functions: a cell biological perspective. Inflamm Allergy Drug Targets. 2010;9:214-228.
20. Theoharides TC, Alysandratos KD, Angelidou A, et al. Mast cells and inflammation. Biochim Biophys Acta. 2012;1822:21-33.
21. Eechoute K, van Zonneveld M, van Daele PL, Gerth van Wijk R, Mathijssen RH. Suppressing effects of sunitinab on allergic rhinitis: previously undefined side effects with therapeutic potential. J Clin Pharmacol. 2011;51:1592-1595.
22. Mughal TI, Schrieber A. Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase. Biologics. 2010;4:315-323.
23. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med. 2005;353:1711-1723.
24. Zhou J, Liu DF, Liu C, et al. Glucocorticoids inhibit degranulation of mast cells in allergic asthma via nongenomic mechanism. Allergy. 2008;63:1177-1185.
25. Lippert U, Möller A, Welker P, Artuc M, Henz BM. Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1- and H2-receptor antagonists. Exp Dermatol. 2000;9:118-124.
26. Shin HY, Kim JS, An NH, Kim HM. Effect of disodium cromoglycate on mast cell-mediated immediate-type allergic reactions. Life Sci. 2004;74:2877-2887.
27. Fischer SGL, Zuurmond WWA, Birklein F, Loer SA, Perez RSGM. Anti-inflammatory treatment of complex regional pain syndrome. Pain. 2010;151:251-256.
28. Choo-Kang BS, Hutchison S, Nickdel MB, et al. TNF-blocking therapies: an alternative mode of action? Trends Immunol. 2005;26:518-522.
29. Huygen FJ, Niehof S, Zijlstra FJ, van Hagen PM, van Daele PL. Successful treatment of CRPS 1 with anti-TNF. J Pain Symptom Manage. 2004;27:101-103.
30. Bernateck M, Rolke R, Birklein F, Treede RD, Fink M, Karst M. Successful intravenous regional block with low-dose tumor necrosis factor-α antibody infliximab for treatment of complex regional pain syndrome 1. Anesth Analg. 2007;105:1148-1151.
31. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med. 1991;173:699-703.
32. Rajkumar SV, Fonseca R, Witzig TE. Complete resolution of reflex sympathetic dystrophy with thalidomide treatment. Arch Intern Med. 2001;161:2502-2503.
33. Ching DW, McClintock A, Beswick F. Successful treatment with low-dose thalidomide in a patient with both Behçet's disease and complex regional pain syndrome type 1: case report. J Clin Rheumatol. 2003;9:96-98.
34. Schwartzman RJ, Chevlen E, Bengtson K. Thalidomide has activity in treating complex regional pain syndrome. Arch Intern Med. 2003;163:1487-1488.
35. Patel AM, Moreland LW. Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy. Drug Des Devel Ther. 2010;4:263-278.
36. Woolf CJ, Decosterd I. Implications of recent advances in the understanding of pain pathophysiology for the assessment of pain in patients. Pain. 1999;(Suppl 6):S141-S147.